| INTRODUC TI ONHydroxychloroquine (HCQ) is an antimalarial drug that has been used commonly in various countries to treat systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), rheumatoid arthritis, and other inflammatory diseases. 1 HCQ was banned for a long time in Japan because of severe chloroquine retinopathy and was reapproved in 2015 as a first-line treatment for CLE. 2 CLE manifestations are wide-ranging, occasionally including mucous involvement of the lip, the tongue, and the buccal and nasal mucosa. 3 It is essential for dental practitioners to be familiar with CLE clinical manifestations and treatments, because CLE patients may present at dental clinics for their initial and main manifestations. However, in the field of dental medicine, no cases have addressed the effectiveness of HCQ for oral mucosal lesions in CLE. We present a case of CLE whose oral lesions were successfully treated with HCQ in close cooperation with dermatologists.
| C A S E REP ORTA 76-year-old male was referred to the dental medicine and dermatology departments of our institution with a 12-month history of erosions on the lower lip and a 16-month history of erythematous macules on the skin. Physical examinations revealed multiple infiltrating erythematous plaques on the back, arms and palms, and painful erosions on the lower lip ( Figure 1A,B).Histopathological examinations of mucosa from the lower lip revealed hyperkeratosis, the thinning of the epithelium and the vacuolar degeneration of the basal cell layer accompanied by noticeable civatte bodies on the epidermis (Figure 2A). Perivascular infiltrates of lymphocytes and plasma cells associated with interstitial mucin deposition were observed in the dermis ( Figure 2B).
Direct immunofluorescence showed linear deposition of C3 andIgM at the basement membrane zone ( Figure 3A). Multiple civatte bodies within the epidermis were clearly detected by fibrinogen staining ( Figure 3B). Systemic involvement suggestive of SLE, such as renal dysfunction, hemolytic anemia, and neurologic disease, was not detected. Considering all of the findings, we diagnosed the case as CLE with oral mucosal lesions. We administered a topical steroid and an oral rinse of azulene sodium salfanate, which proved ineffective. Therefore, HCQ (200 mg and 400 mg on alternate days) was introduced. One month later, the multiple rashes on the skin and erosions on the oral mucosa had resolved ( Figures 4A,B and 5).
AbstractCutaneous lupus erythematosus (CLE) is a rare, potentially disfiguring, chronic autoimmune disease with extremely variable skin and mucosal membrane manifestations.Hydroxychloroquine (HCQ) is an antimalarial drug that has been used in various countries to treat autoimmune diseases including CLE. HCQ was banned for a long time in Japan because of severe chloroquine retinopathy and was reapproved as a first-line treatment for CLE in 2015. There are no case reports describing the effectiveness of HCQ for CLE with oral mucosal lesions in the dental field. We present a case of CLE w...